Modelling liver diseases from acute and chronic injury to hepatocellular carcinoma for development of new treatments

ADCs optimization led to a significant anti-tumoral activity in lymphoma and breast tumor xenograft mouse models

NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA

NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA

Brothers in Arms to support small molecule drug discovery, from Hit to IND

The DRIVE™ offering provides the best options to advance the drug in the shortest possible time with the highest quality.

[WEBINAIRES] CAHIER DE VACANCES DE L’ÉTÉ

[EN] How to better predict your drug efficacy to combat liver diseases?

Optimize drug efficacy prediction : Study of liver pathogenes and liver diseases models in drug development to provide solutions for patients

[EN] How to assess the interplay between tumor, microbiota and therapies? A comprehensive platform to investigate bacteria as immuno-modulating vectors or agents.

[EN] How to recruit immune cells against tumor? Bispecific compounds are the key for new oncology therapeutic strategy

Novel fluorescent probes evaluated in an orthotopic pancreatic PDX model

Novel fluorescent probes evaluated in an orthotopic pancreatic PDX model

[EN] How to better predict the effect of cancer immunotherapy? Tailored-made humanized mouse models are the key solution!

Oncodesign and HitGen announce a strategic partnership in Integrated Drug Discovery Services (IDDS)

Bioanalytical challenges with BioChaperone® BC structures

We wish to develop and validate LC-MS/MS methods for the quantitation of both BioChaperone® BCXXX (Parent) and its truncated metabolite BCYYY inSprague-Dawley rat, Beagle dog and human plasma following the current international guidelines for industry?